Cerebral Therapeutics announced that the first patient has been enrolled in a Phase 2b study of intracerebroventricular drug delivery of the anti-seizure medication CT-010 in patients with medically refractory epilepsy.
18 Nov 2020
05 Nov 2020
NanOlogy enrols first patient in phase 2 trial of NanoPac for intratumoral treatment of prostate cancer
NanOlogy LLC, a clinical-stage oncology company advancing intratumoral therapy for solid tumors, has enrolled the first patient in a Phase 2 clinical trial of NanoPac (sterile nanoparticulate paclitaxel) for suspension via intratumoral injection for local prostate cancer.
02 Nov 2020
Humanigen, a clinical stage biopharmaceutical company focused on preventing and treating an immune hyper-response called ‘cytokine storm’ with lenzilumab, today announced that MedStar Washington Hospital Center in Washington, D.C. treated its first Covid-19 patient with lenzilumab.
22 Oct 2020
ImmunityBio and NantKwest have dosed the first patient in phase I clinical study of a novel Covid-19 vaccine candidate called hAd5-Covid-19.
12 Oct 2020
Rigel Pharmaceuticals has recruited the first patients in a phase 2 study designed to assess the safety of fostamatinib for the treatment of hospitalised Covid-19 patients.
09 Oct 2020
As the number of COVID-19 cases and deaths continues to rise in most countries, Australian clinical-stage drug development company Noxopharm is pleased to announce treatment of the first patient with its lead pipeline candidate, Veyonda, in the company’s Phase 1 NOXCOVID-1 study.
14 Sep 2020
Pfizer and BioNTech announced that they have submitted an amended protocol to the U.S. Food and Drug Administration to expand the enrollment of their Phase 3 pivotal COVID-19 vaccine trial to up to approximately 44,000 participants which also allows for the enrollment of new populations.
07 Sep 2020
Ampio Pharmaceuticals, a biopharmaceutical company focused on the advancement of immunology-based therapies for prevalent inflammatory conditions announces the following:
02 Sep 2020
Clear Creek Bio has dosed the first patient in phase 1 clinical study of brequinar in hospitalised patients with Covid-19.
01 Sep 2020
Orpheris, a wholly-owned subsidiary of Ashvattha Therapeutics, a biotech company focused on developing novel hydroxyl dendrimer therapeutics (HDTs) to treat unmet medical needs in inflammatory, oncology and ocular diseases, today announced enrollment of the first patients in its multicenter Phase 2 PRANA clinical study of the HDT, OP-101, to treat hospitalized adults with severe Covid-19.